Tanvex BioPharma, Inc. (TPE: 6541)

Tanvex BioPharma Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 12, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	11,580	8,715	12,377	20,476	9,894	10,921
Market Cap Growth	-25.41%	-29.59%	-39.56%	106.96%	-9.41%	-27.99%
Enterprise Value	12,278	9,691	13,133	19,692	9,494	9,325
Last Close Price	70.60	64.48	102.15	169.08	107.83	126.41
PE Ratio	-	-3.89	-7.32	-11.90	-4.59	-4.55
PS Ratio	286.19	141.91	552.43	3787.62	32979.06	-
PB Ratio	7.84	10.61	8.89	7.33	3.78	3.60
P/FCF Ratio	-5.06	-5.79	-8.67	-14.45	-5.34	-5.49
P/OCF Ratio	-5.50	-6.08	-9.28	-14.76	-5.53	-5.75
EV/Sales Ratio	267.22	157.80	586.21	3642.61	31645.92	-
EV/EBITDA Ratio	-5.52	-4.90	-8.80	-13.16	-4.85	-4.27
EV/EBIT Ratio	-5.17	-4.61	-8.18	-12.31	-4.52	-4.01
EV/FCF Ratio	-8.29	-6.44	-9.20	-13.90	-5.12	-4.69
Debt / Equity Ratio	1.18	2.11	1.32	0.63	0.58	0.11
Debt / FCF Ratio	-1.17	-1.15	-1.29	-1.24	-0.82	-0.17
Asset Turnover	0.01	0.02	0.01	0.00	0.00	-
Inventory Turnover	0.21	0.01	0.32	0.03	0.00	-
Quick Ratio	3.25	1.15	2.68	9.06	5.93	8.98
Current Ratio	3.64	1.66	3.44	9.67	6.41	9.63
Return on Equity (ROE)	-110.65%	-193.18%	-78.41%	-56.99%	-74.47%	-62.77%
Return on Assets (ROA)	-31.29%	-42.47%	-24.67%	-22.00%	-33.03%	-36.14%
Return on Capital (ROIC)	-32.71%	-45.40%	-25.78%	-22.99%	-34.93%	-38.35%
Earnings Yield	-18.29%	-24.52%	-13.26%	-7.54%	-21.27%	-20.82%
FCF Yield	-12.78%	-17.27%	-11.53%	-6.92%	-18.74%	-18.20%
Buyback Yield / Dilution	-16.01%	-9.60%	-8.31%	-21.32%	-9.25%	-7.87%
Total Shareholder Return	-16.01%	-9.60%	-8.31%	-21.32%	-9.25%	-7.87%

Source: S&P Capital IQ. Standard template. Financial Sources.